ES2886859T3 - Terapia usando un inhibidor del factor xii en un trastorno neurotraumático - Google Patents

Terapia usando un inhibidor del factor xii en un trastorno neurotraumático Download PDF

Info

Publication number
ES2886859T3
ES2886859T3 ES15741128T ES15741128T ES2886859T3 ES 2886859 T3 ES2886859 T3 ES 2886859T3 ES 15741128 T ES15741128 T ES 15741128T ES 15741128 T ES15741128 T ES 15741128T ES 2886859 T3 ES2886859 T3 ES 2886859T3
Authority
ES
Spain
Prior art keywords
fxii
seq
inhibitor
mice
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15741128T
Other languages
English (en)
Spanish (es)
Inventor
Christoph Kleinschnitz
Marc Nolte
Anna-Leena Siren
Christiane Albert-Weissenberger
Sarah Hopp-Kraemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Application granted granted Critical
Publication of ES2886859T3 publication Critical patent/ES2886859T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES15741128T 2014-06-18 2015-06-18 Terapia usando un inhibidor del factor xii en un trastorno neurotraumático Active ES2886859T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172910 2014-06-18
PCT/EP2015/063760 WO2015193457A1 (en) 2014-06-18 2015-06-18 Therapy using a factor xii inhibitor in a neurotraumatic disorder

Publications (1)

Publication Number Publication Date
ES2886859T3 true ES2886859T3 (es) 2021-12-21

Family

ID=50972542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15741128T Active ES2886859T3 (es) 2014-06-18 2015-06-18 Terapia usando un inhibidor del factor xii en un trastorno neurotraumático

Country Status (12)

Country Link
US (2) US20170114119A1 (cg-RX-API-DMAC7.html)
EP (1) EP3157548B1 (cg-RX-API-DMAC7.html)
JP (1) JP7109160B2 (cg-RX-API-DMAC7.html)
KR (1) KR102513050B1 (cg-RX-API-DMAC7.html)
CN (1) CN106456778A (cg-RX-API-DMAC7.html)
AU (1) AU2015276089B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016029624A2 (cg-RX-API-DMAC7.html)
CA (1) CA2950988C (cg-RX-API-DMAC7.html)
DK (1) DK3157548T3 (cg-RX-API-DMAC7.html)
ES (1) ES2886859T3 (cg-RX-API-DMAC7.html)
PL (1) PL3157548T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015193457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157548B1 (en) 2014-06-18 2021-08-04 CSL Behring GmbH Therapy using a factor xii inhibitor in a neurotraumatic disorder
CA3018375A1 (en) * 2016-03-30 2017-10-05 Carin Sjolund Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
KR20180132831A (ko) * 2016-04-06 2018-12-12 시에스엘 리미티드 죽상동맥경화증의 치료 방법
AU2018382222B2 (en) 2017-12-15 2025-09-04 Csl Limited Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2020113084A1 (en) * 2018-11-28 2020-06-04 Oregon Health & Science University Therapeutic factor xii antibody
EP4333901A4 (en) * 2021-05-03 2025-07-09 Harvard College FC FUSION PROTEIN-BASED THERAPEUTIC AGENT FOR THE TREATMENT OF PANCREATITIS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU7793291A (en) 1990-05-10 1991-11-27 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
EP0793504B1 (en) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
UA87458C2 (ru) 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
CN1871252A (zh) 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
PL1830924T3 (pl) 2004-12-23 2013-08-30 Csl Behring Gmbh Zapobieganie tworzeniu i/lub stabilizacji skrzepu
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
KR20200116546A (ko) 2010-12-17 2020-10-12 안트로제네시스 코포레이션 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌 손상의 치료
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
KR101954052B1 (ko) 2011-03-09 2019-03-06 체에스엘 베링 게엠베하 인공 표면과의 접촉을 포함하는 의료 시술에 투여하기 위한 인자 ｘｉｉ 억제제
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
MX347454B (es) 2011-07-22 2017-04-27 Csl Ltd Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
JP6190368B2 (ja) 2011-09-24 2017-08-30 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
DK2964255T3 (da) 2013-03-08 2021-02-08 Csl Behring Gmbh Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
US9587903B2 (en) 2014-02-24 2017-03-07 Brian E. Sullivan Pneumatic launcher system and method
EP3157548B1 (en) 2014-06-18 2021-08-04 CSL Behring GmbH Therapy using a factor xii inhibitor in a neurotraumatic disorder
KR20180132831A (ko) 2016-04-06 2018-12-12 시에스엘 리미티드 죽상동맥경화증의 치료 방법

Also Published As

Publication number Publication date
US20200131248A1 (en) 2020-04-30
PL3157548T3 (pl) 2022-01-17
AU2015276089A1 (en) 2017-02-02
WO2015193457A1 (en) 2015-12-23
EP3157548B1 (en) 2021-08-04
JP7109160B2 (ja) 2022-07-29
US12065481B2 (en) 2024-08-20
KR102513050B1 (ko) 2023-03-29
CA2950988A1 (en) 2015-12-23
US20170114119A1 (en) 2017-04-27
JP2017524675A (ja) 2017-08-31
EP3157548A1 (en) 2017-04-26
DK3157548T3 (da) 2021-09-06
KR20170016503A (ko) 2017-02-13
CA2950988C (en) 2024-02-06
BR112016029624A2 (pt) 2017-10-24
CN106456778A (zh) 2017-02-22
AU2015276089B2 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
ES2886859T3 (es) Terapia usando un inhibidor del factor xii en un trastorno neurotraumático
ES2687018T3 (es) Inhibidores de factor XII para el tratamiento de trastornos inflamatorios neurológicos
ES2973572T3 (es) Formulaciones de anticuerpos humanos anti-RANKL, y métodos de uso de los mismos
KR102456742B1 (ko) 항체 함유 제제
TWI797073B (zh) 包含雙特異性抗體建構物之醫藥組合物
ES2753183T3 (es) Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal
ES2897500T3 (es) Formulaciones de anticuerpos T1h
ES2271515T3 (es) Composiciones farmaceuticas que comprenden lecitina de union a manosa.
US20190062428A1 (en) Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
KR20210134926A (ko) 항-cd47 항체를 포함하는 제제, 이의 제조 방법 및 이의 용도
CN120051296A (zh) 用于施用到软组织的因子ix变体多肽
HK1232804B (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
ES2784842T3 (es) Objetivo dual de TAFI y PAI-1
HK1220132B (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor
BR112016011441B1 (pt) Formulação liofilizada, solução aquosa, e, métodos para preparar uma formulação liofilizada e uma solução injetável